हिंदी में पढ़ें

Lupin share price

Lupin Q2 preview: New launches and approvals to likely aid 37% growth in profit

Lupin Q2 preview: New launches and approvals to likely aid 37% growth in profit

Thu, Nov 07, 2024

New product launches and approvals will help the pharma major to report improved Q2 results.

Lupin shares jump 6%, hit 52-week high amid strong Q1FY25 earnings

Lupin shares jump 6%, hit 52-week high amid strong Q1FY25 earnings

Wed, Aug 07, 2024

Lupin Q1 earnings: Lupin reported 77 per cent hike in its net profit to Rs 801 crore for the June quarter of FY25. This is due to robust sales across markets, the company said in an exchange filing on Tuesday, August 6.

Why stock of this large-cap pharma firm rose nearly 6% in today's trade; know share price target

Why stock of this large-cap pharma firm rose nearly 6% in today's trade; know share price target

Thu, Jul 04, 2024

Lupin shares saw significant rise on Thursday after brokerage double uprgraded it to 'add'. It has given 12-month target of Rs 1,805 for the stock.

TRENDING NOW

5 Stocks for Next 15 Days: Brokerage picks shares for short duration, note down targets and stop losses

5 Stocks for Next 15 Days: Brokerage picks shares for short duration, note down targets and stop losses

Fri, May 17, 2024

5 Stocks for Next 15 Days: Axis Direct has selected 5 stocks for positional traders for 15 days. Know complete details of investment including their names, targets, stoploss.

Top 7 large- and mid-cap healthcare stocks that have given at least 88% return in 1 year

Top 7 large- and mid-cap healthcare stocks that have given at least 88% return in 1 year

Mon, May 13, 2024

Healthcare stocks have been one of the stock gainers in the last one years. Their rise quickened specially after the coronavirus pandemic when the demand for medicines and healthcare facilities increased many folds.

Lupin rises after US FDA gives pharma firm EIR for its Aurangabad facility

Lupin rises after US FDA gives pharma firm EIR for its Aurangabad facility

Wed, Apr 24, 2024

Lupin said on Tuesday that it had received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

Is their more juice left in this large-cap pharma stock after doubling in 1 year?

Is their more juice left in this large-cap pharma stock after doubling in 1 year?

Thu, Feb 08, 2024

Lupin's revenue from operation soared by 20 per cent to Rs 5197 crore in Q3 against Rs 4322 crore Year-on-Year (YoY), compared to estimates of Rs 4868 crore. The firm's EBITDA for the third quarter was 1037 crore in the quarter under review against Rs 532 crore in the same quarter last fiscal, which translated into a leap of 95 per cent. It comfortably beat analysts' estimates of Rs 857 crore.

Lupin stock rises to 52-week high after pharma firm beat Street estimates in December quarter results

Lupin stock rises to 52-week high after pharma firm beat Street estimates in December quarter results

Thu, Feb 08, 2024

The company reported four times jump in its consolidated profit after tax, which skyrocketed to Rs 613 crore in the December quarter compared to Rs 153 crore Year-on-Year (YoY), against Zee Business research estimates of Rs 427 crore.

Lupin trades flat after launch of Bromfenac Ophthalmic Solution

Lupin trades flat after launch of Bromfenac Ophthalmic Solution

Wed, Jan 10, 2024

Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.

Lupin shares surge 3% as USFDA grants approval for gout and diabetes Drugs

Lupin shares surge 3% as USFDA grants approval for gout and diabetes Drugs

Mon, Dec 18, 2023

Lupine gets approval for 2 medicines from USFDA, both medicines will be produced in Pithampur Plant. Diabetes medicine Sitagliptin tablet gets USFDA approval, know the complete news in this video....

Lupin stock rises nearly 3% after US FDA approves Allopurinol tablets

Lupin stock rises nearly 3% after US FDA approves Allopurinol tablets

Mon, Dec 18, 2023

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application for Allopurinol tablets USP, 100 mg and 300 mg. The drug will be manufactured at Lupin’s Pithampur facility in India.

Lupin trades higher after US FDA gives a go-ahead to its Varenicline tablets

Lupin trades higher after US FDA gives a go-ahead to its Varenicline tablets

Wed, Dec 06, 2023

"Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment. Varenicline Tablets (RLD Chantix®) had estimated annual sales of USD 430 million in the U.S. (IQVIA MAT October 2023)," said Lupin in a statement.

Lupin eyes Rs 2,500-crore market with its latest launch in US; what Anil Singhvi recommends

Lupin eyes Rs 2,500-crore market with its latest launch in US; what Anil Singhvi recommends

Mon, Jun 05, 2023

Zee Business Managing Editor Anil Singhvi said he remained upbeat on Lupin shares on account of the company's positive business outlook.

Lupin plant gets 10 observations from US regulator; shares under pressure

Lupin plant gets 10 observations from US regulator; shares under pressure

Fri, Mar 31, 2023

The US Food and Drug Administration (USFDA) inspected Lupin's Pithampur plant from March 21 to March 29, 2023, and ended the inspection by issuing a Form-483 with ten observations, the drugmaker said in a filing. Lupin shares have been a top loser in the pharma pack today.

Lupin shares jumped over 3% on Strong Q2 Results, Brokerage recommends Buy tags–Check target price

Lupin shares jumped over 3% on Strong Q2 Results, Brokerage recommends Buy tags–Check target price

Thu, Nov 10, 2022

Shares of Lupin rallied 3% on Nov 10 after the company announced a consolidated net profit of Rs 130 crore for September quarter 2022-23

Lupin jumps 5% on strong Q2 performance; brokerages tag BUY - check price targets

Lupin jumps 5% on strong Q2 performance; brokerages tag BUY - check price targets

Thu, Nov 10, 2022

Lupin Share Price: The drug maker on Wednesday said its consolidated net profit stood at Rs 130 crore for the second quarter ended September 30, 2022.

Lupin gets USFDA nod for generic HIV drug

Lupin gets USFDA nod for generic HIV drug

Tue, Oct 04, 2022

Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets.

Lupin share price rose 2.5% after the company received USFDA approval for new drug to treat overactive bladder

Lupin share price rose 2.5% after the company received USFDA approval for new drug to treat overactive bladder

Fri, Sep 30, 2022

Lupin share price jumped nearly 2.5% to Rs 682 per share levels on the BSE intraday after the company received USFDA approval for Mirabegron Tablets or Generic Myrbetriq

Lupin jumps 4.5% as pharma firm gets US FDA nod for new drug to treat overactive bladder

Lupin jumps 4.5% as pharma firm gets US FDA nod for new drug to treat overactive bladder

Fri, Sep 30, 2022

Lupin share price on Friday jumped over 4 per cent as it received the US FDA nod for manufacturing a new drug to treat overactive bladder at the company's facility in Nagpur.

Rakesh Jhunjhunwala Stocks - Lupin: How well will it do? Highlights here

Rakesh Jhunjhunwala Stocks - Lupin: How well will it do? Highlights here

Mon, Feb 15, 2021

Ace investor Rakesh Jhunjhunwala holds 72.5 lk shares of Lupin or 1.6% stake in the company. The value of his holding in Lupin is Rs 775 cr. The market cap of Lupin is Rs 48000 cr. The current share price of Lupin is Rs 1060, up Rs 7.5 or 0.7%. Notably, the Big Bull Rakesh Jhunjhunwala had been extremely bullish on Lupin.

Stock investment update: Ace investor Rakesh Jhunjhunwala removes money in this pharma-major - What should you do?

Stock investment update: Ace investor Rakesh Jhunjhunwala removes money in this pharma-major - What should you do?

Thu, Jan 17, 2019

Although, the ace investor has removed his money in Lupin on a marginal basis in Q3FY19, what is interesting to know is that this would be his second selling in this company.

Lupin launches pain relief drug in US; shares rise

Lupin launches pain relief drug in US; shares rise

Thu, Mar 09, 2017

Drug firm Lupin today announced the launch of pain relief drug Hydrocodone Bitartrate and Acetaminophen in the US market.

Lupin's Q3 net profit rise by 21%; shares trade high

Lupin's Q3 net profit rise by 21%; shares trade high

Thu, Feb 09, 2017

Pharmaceutical-major Lupin on Thursday reported 21% rise in net profit during the quarter ended on December 31.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x